Reliable biomarkers for monitoring and predicting disease course, stage and progression are invaluable. They offer particular value in therapeutic decision-making when there is a risk of severe adverse events.
Autoantibody biomarkers can be used to establish signatures for predicting if patients are likely to respond to treatment. These predictive signatures can also be used to identify patient populations likely to experience adverse events.
Having the ability to interrogate many autoantibody targets in a single assay can help accelerate the identification and validation of signatures with high predictive value.